Summary: Increasing levels of the MFN1 protein counterbalances mutated MFN2, reducing symptoms associated with Charcot-Marie-Tooth disease and neurodegeneration in mouse models.
Source: Cedars Sinai Medical Center
A new study provides critical insight into a little-known, yet relatively common, inherited neurological condition called Charcot-Marie-Tooth disease. The findings point to a pathway to possible treatments for this disease and a better understanding of other neurodegenerative disorders, including Alzheimer’s disease, that affect millions.
The study focused on two related proteins, MFN2 and MFN1, found on the outer membranes of mitochondria — structures inside the body’s cells that act as powerhouses by converting food into energy. Mitochondria play an especially critical role in nerve cells. Previous research has shown that mutated MFN2 causes mitochondria to malfunction in a common type of Charcot-Marie-Tooth disease — CMT type 2A.
The new research, published in the April 1 issue of the Journal of Clinical Investigation, showed that increasing levels of MFN1 to counterbalance mutated MFN2 reduced symptoms of CMT type 2A and neurodegeneration in laboratory mice.
The multi-institutional study was co-led by Robert Baloh, MD, Ph.D., professor of Neurology, Ben Winters Chair in Regenerative Medicine and director of Cedars-Sinai Center for Neural Science and Medicine; and Yueqin Zhou, Ph.D., a postdoctoral researcher in his laboratory.
Charcot-Marie-Tooth disease affects an estimated 150,000 people in the U.S., according to the National Institutes of Health. It typically causes weakness, numbness, muscle cramps and movement problems in legs and arms. The CMT type 2A form of the disease also may cause wasting of the optic nerve, spinal cord damage leading to difficulty walking, hearing loss, developmental delay and changes in vital tissues of the brain known as white matter.
Despite the fact that mutated MFN2 can be expressed in every cell in the body, CMT type 2A primarily affects the nervous system. This is because levels of MFN1 are particularly low in brain cells, and restoring those levels can improve mitochondrial function. That fact is significant, Baloh said, “because findings about CMT2A can go beyond just a single disease. The hope is that similarly increasing MFN1 potentially could treat other neurodegenerative diseases that also involve mitochondrial dysfunction.”
These other diseases include Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, which all have devastating consequences. Collectively, these three diseases are believed to affect about 7 million people in the U.S. Despite much research, the causes of these disorders and Charcot-Marie-Tooth disease remain elusive.
Because of their relevance to CMT type 2A and other neurodegenerative conditions, mitochondrial proteins have been the focus of intense study in recent years. Previous laboratory studies showed that the protein MFN1 could compensate for the loss of function of mutated MFN2. The new study advances these findings by testing the approach in laboratory mice.
To perform this experiment, the investigators incorporated a human gene with the mutation that causes the disease into the genome of the mouse. This technique allowed them to study CMT type 2A over the lifetime of the lab animal.
Mice with the mutated gene developed symptoms of CMT type 2A. Importantly, when levels of MFN1 or normal MFN2 were increased in mice with CMT type 2A, the disease process almost completely stopped. “It appears that MFN1 helps take over the work of the disabled, mutated protein in mice,” Baloh said.
This finding raises the possibility that increasing levels of MFN1 using gene therapy or other approaches might in the future be used to treat patients with CMT type 2A and also other neurodegenerative diseases that involve mitochondrial dysfunction, he added.
Funding: Research reported in this publication was supported by the National Institutes of Health under award numbers NS055980, NS097545, AG056678 and R35HL135736; the Muscular Dystrophy Association; the Charcot-Marie-Tooth Association; and a McDonnell Center for Cellular and Molecular Neurobiology postdoctoral fellowship.
Cedars Sinai Medical Center
Jane Engle – Cedars Sinai Medical Center
The image is credited to National Institute of Mental Health, National Institutes of Health.
Original Research: Open access
“Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model”
Yueqin Zhou, Sharon Carmona, A.K.M.G. Muhammad, Shaughn Bell, Jesse Landeros, Michael Vazquez, Ritchie Ho, Antonietta Franco, Bin Lu, Gerald W. Dorn II, Shaomei Wang, Cathleen M. Lutz, and Robert H. Baloh Journak of Clinical Investigation. doi:10.1172/JCI124194
Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model
Mitofusin-2 (MFN2) is a mitochondrial outer-membrane protein that plays a pivotal role in mitochondrial dynamics in most tissues, yet mutations in MFN2, which cause Charcot-Marie-Tooth disease type 2A (CMT2A), primarily affect the nervous system. We generated a transgenic mouse model of CMT2A that developed severe early onset vision loss and neurological deficits, axonal degeneration without cell body loss, and cytoplasmic and axonal accumulations of fragmented mitochondria. While mitochondrial aggregates were labeled for mitophagy, mutant MFN2 did not inhibit Parkin-mediated degradation, but instead had a dominant negative effect on mitochondrial fusion only when MFN1 was at low levels, as occurs in neurons. Finally, using a transgenic approach, we found that augmenting the level of MFN1 in the nervous system in vivo rescued all phenotypes in mutant MFN2R94Q-expressing mice. These data demonstrate that the MFN1/MFN2 ratio is a key determinant of tissue specificity in CMT2A and indicate that augmentation of MFN1 in the nervous system is a viable therapeutic strategy for the disease.